We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GENENTECH REVISES CARDIOVASCULAR WARNINGS FOR AVASTIN
GENENTECH REVISES CARDIOVASCULAR WARNINGS FOR AVASTIN
August 13, 2004
Genentech has updated the labeling and package inserts for its Avastin anticancer drug to include additional warnings about cardiovascular risks associated with the use of the drug.